Abstract: A method for the quantification of an antigen, antibody, or antigen-antibody complex in a sample solution involving measuring the results of an immunochemical agglutination reaction or an agglutination inhibition reaction by spectrophotometry, wherein after the initiation of the agglutination between the antigen, antibody, or antigen-antibody complex to be determined and sensitized carrier particles to which a substance specifically bindable to the said antigen, antibody, or antigen-antibody complex is bound, a fixing compound is added to fix aggregates formed by the agglutination. A measuring reagent kit or pack includes all the components for use in carrying out the above method.

Abstract: Therapeutic agent for the treatment of allergic disorders, immune complex diseases and tumors, which contains a human urinary acid protease as an active ingredient, and a method for treating allergic disorders, immune complex diseases and tumors by administering the said acid protease, which has never been used as a therapeutic agent for allergic disorders, immune complex diseases and tumors. Since the acid protease is a protein of human origin, the probability of adverse reactions such as anaphylactic shock due to the antigenicity of the acid protease is believed to be extremely small.

Abstract: There are disclosed azo compounds represented by the formula: ##STR1## wherein X is hydrogen or halogen. The azo compounds are useful as precursors of disperse dyes and basic dyes and are effective for therapeutic treatment.

Abstract: Target Cell Lysis Factor (TCLF) is produced by exposing a human cell line capable of producing TCLF to a TCLF inducer to induce TCLF production, and collecting and purifying the accumulated TCLF. The TCLF which is produced includes lymphotoxin and human Tumor Necrosis Factor (hTNF). The hTNF may be separated and purified. The human cell lines are preferably human leucocyte and human lymphoblastoid lines, such as BALL-1, TALL-1, NALL-1 Namalwa, MOLT-3, Mono-1, M-7002, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41 and CCRF-SB, as well as human cell lines which are obtainable by transforming normal human monocytes, or granulocytes. All of these human cell lines are multipliable by implanting them in a non-human warm-blooded animal, or alternatively, allowing them to multiply in a conventional-type diffusion chamber by which the nutrient body fluid of a non-human warm-blooded animal is supplied to them.

Abstract: A pharmaceutical composition having diuretic, hypotensive and antiedemic effects which contains a 6-halo-4-oximino-1,2,3,4-tetrahydroquinoline derivative or a salt thereof, and a method to use the above-described derivative or a salt thereof as a diuretic, hypotensive and antiedemic agent.

Abstract: 4-oximino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I): ##STR1## wherein X represents a halogen atom and Y represents a hydrogen atom, a straight-chain or branched-chain alkyl group, a halogen-substituted lower alkyl group, a phenylalkyl group, a phenylalkenyl group, an unsubstituted or halogen-substituted phenyl group, a nitrogen-containing aromatic group, a straight-chain or branched-chain alkoxy group or an alkyl-substituted or phenyl-substituted amino group.

Abstract: A method for the quantification of an antigen, antibody, or antigen-antibody complex in a sample solution involving measuring the results of an immunochemical agglutination reaction or an agglutination inhibition reaction by spectrophotometry, wherein after the initiation of the agglutination between the antigen, antibody, or antigen-antibody complex to be determined and sensitized carrier particles to which a substance specifically bindable to the said antigen, antibody, or antigen-antibody complex is bound, a fixing compound is added to fix aggregates formed by the agglutination. A measuring reagent kit or pack includes all the components for use in carrying out the above method.

Abstract: The compositions for therapeutic treatment contain as an active ingredient a 2-[(2-methoxyphenyl)-axo]-1H-imidazole derivative of the formula: ##STR1## wherein X is hydrogen or halogen, or a pharmaceutically acceptable salt thereof. This compound is effective for the therapeutic treatment of edema, hypotension, cardiac insufficiency and mucosa hyperemia.

Abstract: An immunochemical process and the reagents for measuring hapten by using an agglutination inhibition reaction, anti-hapten antibody sensitized particles and a hapten-carrier conjugate which is capable of agglutinating said particles.

Abstract: Immunochemical measurement by either (1) the reaction of the measurement substance with the insolubilized substance and then the reaction of the reaction product of the first procedure with the labeled substance or (2) the reaction of the measurement substance with the labelled substance and then the reaction of the resulting reaction product with the insolubilized substance, or (3) the simultaneous reaction of the three substances.

Abstract: A stabilizer consisting principally of cytochrome c or a thermally modified matter of cytochrome c for maintaining constant over an extended period the sensitivity of measurement and specificity of a measuring reagent on the basis of the immunochemical agglutination reaction and the agglutination inhibition reaction.

Abstract: Immunochemical process of measuring antigenic substances such as human chorionic gonadotropin, growth hormone, insulin, immunoglobulins using a labeled antibody, which makes a monovalent bond to the antigen, and insolubilized antigen.The labeled monovalent antibody used is a monovalent antibody obtained by digesting the antibody to an antigen to be measured with papain according to Porter's method or by reducing a fragment obtained by digesting the antibody with pepsin according to Peterman's method.

Abstract: An immunochemical measuring method using a second antigenic substance and a labeled antibody to the second antigenic substance.An unknown amount of an antigen (Ag 1) to be measured and a given amount of a conjugate (Ag 1-Ag 2) coupled a second antigen (Ag 2) to the Ag 1 are reacted with a given amount of an antibody (Ab 1) to the Ag 1. Ag 1-Ag 2 bind to the Ab 1 in proportion to their respective amount, forming an Ab 1-Ag 1-Ag 2 complex. Then, by reaction of the complex with a labeled antibody (labeled Ab 2) to the Ag 2, Ab 1-Ag 1-Ag 2-labeled Ab 2 is formed. It is possible to estimate the amount of Ag 1 to be measured by determining the activity of labeled Ab 2 attached to the complex.

Abstract: Carrier for immunochemical measurement wherein tannic acid is bound to blood cells in the proportion of 30 to 500 mg per milliliter of the blood cells.

Abstract: A dripping vessel according to the present invention is characterized in that one end of a metal or glass cylinder is closed except for a fine tube projecting therethrough, while the other end of the cylinder is open with a movable plug of fluoro rubber or fluoro resin provided therein. This movable plug can be moved back and forth within said cylinder by the rotation of a screw threaded into said other end of said cylinder or into one end of a casing which holds said cylinder, whereby a desired amount of hardening agent which fills said cylinder can be forced out by the movement of said movable plug.